Alector's AL001 Fast Track'd in U.S. for type of dementia

Dec. 05, 2019 4:37 PM ETAlector, Inc. (ALEC)ALECBy: Douglas W. House, SA News Editor
  • The FDA designates Alector's (NASDAQ:ALEC) lead candidate AL001 for Fast Track review for the treatment of frontotemporal dementia (FTD), a group of brain disorders characterized by atrophy in the lobes of the brain in those areas.
  • Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
  • AL001 is an intravenously administered humanized recombinant monoclonal antibody designed to increase levels of a protein called progranulin in the brain. Mutations in the encoding gene can reduce granulin levels by as much as 70%. In these cases, the probability of developing FTD is greater than 90%.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.